IDH1 and glioma: Based on all these preclinical data, the German National Cancer Center has conducted a multicenter, first-in-humans Phase I trial, evaluating the feasibility, safety, and immunogenicity of a vaccine targeting the IDH1R132H mutant protein among newly diagnosed patients with IDH1-mut glioma (NOA16, NCT02454634) [45,52] (Table 2).